Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effekt af HIgh-flow terapi i langvarig iltterapi (HILOT)

16. november 2026 opdateret af: Magnus Ekström, Skane University Hospital

Effekt af HIgh-flow terapi i langvarig iltterapi (HILOT): Et multicenter, registerbaseret, randomiseret klinisk forsøg

This is a registry-based, randomized, controlled clinical trial of the effect of added high-flow oxygen therapy (using the device Lumis HFT) during one year in people with long-term oxygen therapy (LTOT) for chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This is a registry-based, randomized, controlled clinical trial of patients with LTOT for COPD or ILD recruited using the Swedish National Registry for Respiratory Failure (Swedevox) in collaboration with a research network within the Swedish Respiratory Society. The trial evaluates the effect of added high-flow oxygen therapy nighttime to the regular low-flow oxygen therapy compared with regular low-flow oxygen therapy alone up to one year.

The purpose of this project is to improve evidence-based treatment of people with chronic respiratory failure, currently about 2000 patients annually in Sweden, who have high risk of adverse events and mortality.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

310

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Örebro, Sverige, 70185
        • Rekruttering
        • Department of Heart, Lung and Clinical Physiology, Örebro University Hospital
        • Kontakt:
          • Josefin Sundh, MD, PhD
    • Blekinge County
      • Karlskrona, Blekinge County, Sverige, 37185
        • Rekruttering
        • Research Unit, Blekinge University of Technology
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age 40 years or older
  • Ongoing LTOT: prescribed for at least 15 hours per day; and since at least 28 days as registered in Swedevox
  • COPD or ILD as main underlying reason for LTOT
  • Oxygen concentrator as stationary oxygen source in the home including night-time
  • Body mass index (BMI) < 35 kg/m2

Exclusion Criteria:

  • Current or previous treatment with home HFOT
  • Current treatment with home mechanical ventilation
  • Current treatment with home CPAP
  • Hospitalized during the last 2 weeks
  • Current smoking or contact with flames
  • Self-reported average use of the LTOT < 15h per day (24 hours)
  • PaCO2 (breathing air at rest) > 8 kPa
  • Strong clinical suspicion of obstructive sleep apnea (OSA) or obesity-related hypoventilation syndrome (OHS) (as judged by the responsible staff)
  • Inability to participate in the study procedures (as judged by the staff)
  • Not eligible for continuing LTOT due to other reason (as judged by the staff)
  • Expected survival less than 3 months (as judged by the staff)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: High-flow oxygen therapy

Intervention arm

Added high-flow oxygen therapy using the device Lumis HFT during nighttime and at the patient's discretion daytime, with the usual care (low-flow oxygen therapy) the rest of the time.

Aktiv komparator: Low-flow oxygen therapy

Comparison arm

Standard care with low-flow oxygen therapy in accordance with clinical routine.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to first hospitalization or death from all causes
Tidsramme: 1 year

Time to first hospitalization or death from all causes during 1 year after randomization in people with COPD (assessed using nationwide registry data)

1 year

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to first all-cause hospitalization or all-cause death
Tidsramme: 1 year

Time to first all-cause hospitalization or all-cause death in people with ILD (assessed using nationwide registry data)

1 year
Rate of hospitalizations or death from all causes
Tidsramme: 1 year

Rate of hospitalizations or death from all causes assessed using nationwide registry data

1 year
Hospitalization rate from all causes
Tidsramme: 1 year

Hospitalization rate from all causes assessed using nationwide registry data

1 year
Hospitalization rate from respiratory disease
Tidsramme: 1 year

Hospitalization rate from respiratory disease assessed using nationwide registry data

1 year
Number of hospitalized days
Tidsramme: 1 year

Number of hospitalized days from all-causes, respiratory and cardiovascular disease using nationwide registry data

1 year
Hospitalization rate from cardiovascular disease
Tidsramme: 1 year

Hospitalization rate from cardiovascular disease assessed using nationwide registry data

1 year
Number of admissions to intensive care unit (ICU)
Tidsramme: 1 year

Number of admissions to ICU assessed using nationwide registry data

1 year
Number of days in ICU
Tidsramme: 1 year

Number of days in ICU assessed using nationwide registry data

1 year
Mortality rate from all causes
Tidsramme: 1 year

The mortality rate from all causes assessed using nationwide registry data

1 year
Mortality rate from respiratory disease
Tidsramme: 1 year

The mortality rate from respiratory disease assessed using nationwide registry data

1 year
Mortality rate from cardiovascular disease
Tidsramme: 1 year

The mortality rate from cardiovascular disease assessed using nationwide registry data

1 year
Time to first exacerbation
Tidsramme: 1 year

Time to first exacerbation after randomisation, defined as time to first dispensed antibiotics and/or oral corticosteroids, ED-visit or hospitalization for exacerbation assessed using self-reported and registry data

1 year
Number of exacerbations
Tidsramme: 1 year

Number of exacerbations of all severity assessed using self-reported and registry data

1 year
Incidence of cardiovascular disease
Tidsramme: 1 year

Incidence of cardiovascular disease assessed using nationwide registry data

1 year
Need for home mechanical ventilation
Tidsramme: 1 year

Need for starting home mechanical ventilation assessed using nationwide registry data

1 year
Rate of withdrawal of long-term oxygen therapy
Tidsramme: 1 year

Rate of withdrawal of long-term oxygen therapy assessed using nationwide registry data

1 year
Adverse events
Tidsramme: 3 and 12 months

Self-reported adverse events since study start assessed using a postal questionnaire.

3 and 12 months
Primary care utilization
Tidsramme: 1 year

Self-reported number of primary care contacts since the start of the study assessed using a postal questionnaire.

1 year
Health-related quality of life
Tidsramme: 3 and 12 months

Self-reported health-related quality of life assessed using the EuroQol Five Dimensions - Five Levels (EQ5D-5L) questionnaire.

3 and 12 months
Health status
Tidsramme: 3 and 12 months

Self-reported health status assessed using the and the COPD Assessment Test (CAT) questionnaire.

3 and 12 months
Breathlessness at exertion
Tidsramme: 3 and 12 months

Self-reported exertional breathlessness assessed using the Dyspnoea Exertion Scale (DES) questionnaire.

3 and 12 months
Breathlessness
Tidsramme: 3 and 12 months

Self-reported breathlessness assessed using the Dyspnea-12 questionnaire.

3 and 12 months
Sleep quality
Tidsramme: 3 and 12 months

Self-reported sleep quality assessed using the modified Basic Nordic Sleep Questionnaire.

3 and 12 months
Physical activity
Tidsramme: 3 and 12 months

Self-reported level of physical activity assessed using the modified Grimby-Frändin questionnaire.

3 and 12 months
Change in health status
Tidsramme: 3 and 12 months

Self-reported change in perceived health status assessed using the Global Impression of Change (GIC) scale.

3 and 12 months
Nasal symptoms
Tidsramme: 3 and 12 months

Self-reported nasal symptoms assessed using the modified Björklund questionnaire.

3 and 12 months

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Patient preference for continuing the treatment
Tidsramme: 3 and 12 months

Patients' self-reported patient preference for continuing the treatment assessed using postal questionnaire.

3 and 12 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Magnus Ekström, MD, PhD, Skane University Hospital

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. juni 2024

Primær færdiggørelse (Anslået)

1. december 2028

Studieafslutning (Anslået)

1. december 2029

Datoer for studieregistrering

Først indsendt

17. januar 2024

Først indsendt, der opfyldte QC-kriterier

6. februar 2024

Først opslået (Faktiske)

7. februar 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • HILOT

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

IPD cannot be shared due to restrictions in the current ethical approval. Pseudonymized IPD can be shared upon reasonable request and separate ethical approval.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .